Objective. To compare the efficacy of ceftazidime-avibactam and aztreonam combination therapy with “standard” therapy in patients with hematological malignancies and sepsis, caused by carbapenemresistant K. pneumoniae.
Materials and Methods. In this open, single center prospective-retrospective, cohort study, during 2019–2022, we analyze medical documentation of 81 hospitalized patients with hematologic malignancies and K. pneumoniae sepsis. K. pneumoniae was identified by MALDI-TOF mass-spectrometry; antimicrobial susceptibility testing was performed in accordance with current versions of EUCAST guidelines.